Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19...(Ended December 31 Year % ($ million...),Health

($ millions) 2007 2006 Change 2007 2006 Change

Orthopaedic

Products $7.2 $4.3 67% $13.4 $8.7 54%

Cardiovascular

Products $3.5 $5.2 (32%) $7.4 $10.4 (30%)

Other Products $0.7 $0.4 68% $0.9 $0.7 38%

Total Net

Sales -

Biomaterials $11.5 $10.0 15% $21.7 $19.8 9%

"Sales of orthopaedic products increased $2.9 million in the second quarter of fiscal 2008 over the comparable prior fiscal year quarter, of which approximately $400,000 was due to new product revenue related to the acquisition of the MacroPore Biosurgery assets. The success of the biomaterial products in the end user markets demonstrates the strengths of our core technologies and the accomplishments of our strategic partners. We expect this success will continue over the remainder of our fiscal year. Our biomaterials cardiovascular product sales, as anticipated, decreased year over year and we expect these sales to be relatively steady for the remainder of the fiscal year," commented Joe Kaufmann, President and CEO.

Endovascular Update. "Sales of our endovascular products increased 36% year over year. We are pleased with the notable growth over the past year in our thrombus removal product lines with both our QuickCat(TM) and ThromCat(TM) products. In addition, sales of our Safe-Cross(TM) device for the treatment of chronic total occlusions demonstrated strong growth in the U.S. market. We expect endovascular sales to continue to expand throughout the fiscal year, however as previously noted our U.S. growth has been impacted by the smaller than anticipated size of our sales force. The Company is actively developing second generation products for both the Safe-Cross(TM) and the ThromCat(TM) devices, each of which are expected to be market-ready by the end of the
'/>"/>